SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus, evidenced by massive trading volume and heightened short interest, as the community debates whether the stock is finding a bottom ahead of upcoming earnings. Market participants are actively discussing the potential impact of new defense contract wins and the integration of the DZYNE acquisition on the company's long-term growth and technical recovery.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending as investors react to a technical breakout above resistance levels, fueled by analyst price target upgrades and rising net deposits. The community remains polarized, with bulls pointing to fundamental growth and accumulation as potential catalysts for a squeeze, while skeptics warn of historical patterns of volatility and selling pressure.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital Inc. is trending as investors react to broad sector volatility and headlines surrounding hyperscaler compute utilization, while bullish sentiment persists around the company's strategic pivot into AI infrastructure and its secured power pipeline. The community is actively debating whether the current pullback represents a fundamental shift or a temporary reset, with many investors focusing on the stock's long-term potential as a data center and HPC provider.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is seeing significant market interest and bullish sentiment driven by a favorable antitrust court ruling against Google and ongoing speculation regarding potential strategic partnerships with major tech players like Apple. The community is actively debating the stock's long-term growth potential and fundamental value, with many investors focusing on momentum, institutional accumulation, and the stock's positioning within the expanding fintech and BNPL sectors.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid intense community speculation regarding a potential buyout or hostile takeover, fueled by anomalous trading volume that some observers attribute to index rebalancing while others view as signs of institutional accumulation. Shareholders remain deeply divided, with vocal bears highlighting the stock's long-term stagnant performance and management frustration, while bulls point to the company's valuation gap compared to peers and upcoming pipeline milestones.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending as investors react to a strong quarterly performance marked by an earnings beat and an upward revision to full-year guidance, driven by resilient pricing and robust demand for premium trucks and SUVs. The community is actively debating the sustainability of this momentum, weighing the company's solid operational execution against ongoing EV-related restructuring costs and broader economic uncertainties.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending as investors react to the company's recent leadership transition and the broader sector optimism fueled by executive actions to expedite psychedelic therapy research. Community discussion remains focused on the company's progress with its Phase 3 APPROACH trial for HLP003 and how it positions itself relative to sector peers amidst heightened regulatory attention.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigen is experiencing a significant surge in trading volume and share price as investors react to the company's transition from an R&D focus to a commercial-stage biotech with its FDA-approved Papzimeos treatment. Community discussions are heavily focused on the stock's potential for a short squeeze, its recent breakout above key technical resistance levels, and ongoing speculation regarding future partnership opportunities, European market expansion, and a possible acquisition.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrop Grumman is trending as investors react to strong earnings results, raised future guidance, and active community debate over the companys role in modern defense programs. The stock is currently a focal point for traders weighing the impact of elevated global defense spending and budget priorities against broader sector volatility.

Honeywell Aerospace, Inc. manufactures aircraft engines, avionics, and satellite systems. The private company is located in the US.

Honeywell Aerospace Inc

Honeywell Aerospace

Honeywell Aerospace ($HONA) is facing significant price volatility following its recent spin-off, with investors actively debating whether the decline represents a major buying opportunity or a deeper structural issue. Community discourse is heavily focused on the stock's massive order backlog and recent large-scale contracts, contrasted against frustrations over supply chain constraints and debt-heavy initial positioning.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$DARE 💡👀💡Why the ARPA-H LaunchPad award for Daré Bioscience may be more important than the market currently realizes.

1/ Daré was selected by ARPA-H’s LaunchPad program and can receive up to $10M in milestone-based, non-dilutive funding to advance DARE-HPV. LaunchPad is designed for technologies approaching commercialization—not early-stage academic research.

2/ ARPA-H is modeled after DARPA and is highly selective. Being chosen signals that the U.S. government sees both significant clinical impact and real-world deployment potential.

3/ The support goes beyond funding. Daré also receives commercialization guidance through the LaunchPad Accelerator and collaboration with an Entrepreneur-in-Residence focused on bringing the technology to market.

https://arpa-h.gov/explore-funding/initiatives-and-sprints/sprint-for-womens-health

The Advanced Research Projects Agency for Health (ARPA-H) supports transformative research to drive biomedical and health breakthroughs ranging from molecular to societal to provide transformative health solutions for all.

ARPA-H

Sprint for Women's Health

StockTwits for iOS

Dare Bioscience Inc

 💡👀💡Why the ARPA-H LaunchPad award for Daré Bioscience may be more important than the market currently realizes.

1/ Daré was selected by ARPA-H’s LaunchPad program and can receive up to $10M in milestone-based, non-dilutive funding to advance DARE-HPV. LaunchPad is designed for technologies approaching commercialization—not early-stage academic research.

2/ ARPA-H is modeled after DARPA and is highly selective. Being chosen signals that the U.S. government sees both significant clinical impact and real-world deployment potential.

3/ The support goes beyond funding. Daré also receives commercialization guidance through the LaunchPad Accelerator and collaboration with an Entrepreneur-in-Residence focused on bringing the technology to market.



BuyAndHold

5/ Today, women with persistent HPV infections are often placed in “watchful waiting,” involving repeated doctor visits, monitoring, and sometimes invasive procedures if abnormalities develop. There is currently no approved drug that clears persistent hrHPV infections.

6/ DARE-HPV aims to change this paradigm. It is a vaginal soft-gel insert containing the well-known antiretroviral drugs lopinavir and ritonavir, designed to allow women to treat persistent high-risk HPV infections at home.

7/ By intervening earlier in the disease pathway, this approach could potentially eliminate prolonged monitoring and reduce the need for invasive procedures.

8/ If successful, this model could transform HPV management by enabling early, at-home treatment—reducing healthcare costs and improving access to care, especially for women facing geographic, socioeconomic, or healthcare system barriers.

9/ The overlooked point for investors: ARPA-H support provides non-dilutive funding, scientific validation, and commercialization infrastructure—all of which significantly de-risk development.

10/ For a small biotech, that combination—government validation + funding + commercialization support—can meaningfully improve the probability of bringing a new therapy to market.